Lupin signed an agreement with Celon Pharma for developing generic version of asthma drug
The collaboration is an important milestone in Lupin’s efforts to evolve its global inhalation pipeline.
Mumbai-based drug major Lupin on 17 February 2015 signed an agreement with Poland-based Celon Pharma to jointly develop a generic version of GlaxoSmithKline’s Advair Diskus, a drug used to treat asthma.
Under the agreement, both the companies will jointly develop fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline’s Advair Diskus. But Celon will supply the product to Lupin for its commercialisation in the US, Canada, Mexico, and other key markets.
The collaboration is an important milestone in Lupin’s efforts to evolve its global inhalation pipeline. Lupin’s expertise in inhalation product development and commercialisation in the US and other markets will accelerate the development of generic Advair Diskus for global markets.
GlaxoSmithKline’s Advair Diskus had global sales of over 7 billion US dollar in fiscal year 2014-15.
For the development of inhalation product, Lupin has set up a dedicated centre of excellence for inhalation research in Florida and has been ramping up investments in niche and speciality therapies.
Celon Pharma’s Chief Executive Officer (CEO) and Managing Director is Maciej Wieczorek whereas Lupin’s CEO is Vinita Gupta.